Does SITAGLIPTIN Cause Malignant neoplasm progression? 47 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 47 reports of Malignant neoplasm progression have been filed in association with SITAGLIPTIN (JANUVIA). This represents 0.2% of all adverse event reports for SITAGLIPTIN.
47
Reports of Malignant neoplasm progression with SITAGLIPTIN
0.2%
of all SITAGLIPTIN reports
26
Deaths
26
Hospitalizations
How Dangerous Is Malignant neoplasm progression From SITAGLIPTIN?
Of the 47 reports, 26 (55.3%) resulted in death, 26 (55.3%) required hospitalization, and 8 (17.0%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SITAGLIPTIN. However, 47 reports have been filed with the FAERS database.
What Other Side Effects Does SITAGLIPTIN Cause?
Blood glucose increased (1,427)
Pancreatic carcinoma (1,142)
Product dose omission issue (1,125)
Drug ineffective (1,057)
No adverse event (994)
Nausea (936)
Pancreatitis (922)
Diabetes mellitus inadequate control (744)
Diarrhoea (712)
Hypoglycaemia (674)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which SITAGLIPTIN Alternatives Have Lower Malignant neoplasm progression Risk?
SITAGLIPTIN vs SOAP
SITAGLIPTIN vs SODIUM
SITAGLIPTIN vs SODIUM BICARBONATE
SITAGLIPTIN vs SODIUM BICARBONATE\SODIUM
SITAGLIPTIN vs SODIUM BORATE